Leinco Technologies

Anti-Human CD44 - Purified (Clone F10-44-2)

Product Code:
 
LEI-C562
Product Group:
 
Primary Antibodies
Host Type:
 
Mouse
Antibody Isotype:
 
IgG2a
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
F10-44-2
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Flow Cytometry
  • Immunohistochemistry- Paraffin Embedded (IHC-P)
  • Immunoprecipitation (IP)
Shipping:
 
Ambient
Storage:
 
For use within 1 month of purchase store at 2-8°C. For long term storage freeze working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-C562-0.1mg0.1 mg£663.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Antigen Distribution:
CD44 is expressed on all leukocytes, endothelial cells, hepatocytes, and mesenchymal cells in addition to B-cells, monocytes, macrophages and certain subsets of thymocytes and peripheral T-cells. Mice with the Ly-24.1 allotype have high densities of CD44+ T-cells.
Concentration:
0.1 mg/ml
Conjugate/Tag/Label:
Purified
Format:
This purified monoclonal antibody is formulated in phosphate buffered saline (PBS), 1 mg/ml BSA and 10 mM sodium azide as a preservative.
Formulation:
This purified monoclonal antibody is formulated in phosphate buffered saline (PBS), 1 mg/ml BSA and 10 mM sodium azide as a preservative.
Immunogen:
Purified Human T Cells
Long Description:
CD44 is an 80-95 kD glycoprotein that plays a role in various cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis. CD44 interacts with osteopontin, collagens, and matrix metalloproteinases (MMPs) and is a receptor for hyaluronic acid. Transcripts for this gene go through intricate alternative splicing that result in a variety of functionally distinct isoforms, including those which may be related to tumor metastasis. These splice variants of CD44 function as receptors under hemodynamic flow conditions that are significant to the development of cancer metastasis. Hence, it is thought that anti-CD44 tumor-specific mAbs may have therapeutic potential. This therapeutic potential of anti-CD44 mAbs is evident in some animal experiments demonstrating a reduction in malignant activities of various neoplasms when CD44 was targeted by a combination of mAbs, antisense oligonucleotides, and CD44-soluble proteins. It has been reported that high levels of CD44 on leukemic cells fuel leukemia production. Notably, various cancer studies show conflicting results pertaining to level of CD44 expression and its correlation with disease prognosis. Before anti-CD44 therapy can be applied to human cancers, it is essential to resolve this inconsistency.
NCBI Gene:
960
Target:
CD44

References

1. Leukocyte Typing V (1995) Oxford University Press 2. Shi, S. R. et al. (1995) Cell Vision 2:6 3. Stauder, R. et al. (1995) Immunologist 3:78 4. Favaloro, E. (1993) Immunol. Cell Biol. 71:571 5. Goldstein, L. A. et al. (1990) Immunogenetics 32(6):389 6. Leukocyte Typing IV (1989) Oxford University Press 7. Leukocyte Typing III (1987) Oxford University Press